Richard Pazdur, MD, from the FDA’s Center for Drug Evaluation and Research, describes the benefits of a Breakthrough Therapy Designation.
Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research, describes the benefits of a Breakthrough Therapy Designation.
There have been several drugs in the past that would have benefited from the increased interaction between sponsors and the FDA from a Breakthrough Therapy Designation, Pazdur notes.
The concept behind a Breakthrough Therapy Designation is that the FDA will be involved with the sponsor on an ongoing basis to address clinical application, manufacturing issues, clinical pharmacology issues, and preclinical issues in a timely fashion.
<<<
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More